Recombinant Poliomyelitis Vaccine (CS-2036) | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

24,161 results for “Recombinant Poliomyelitis Vaccine (CS-2036)”

CanSino Biologics Initiates Phase I/II Trial of Recombinant Polio Vaccine in Indonesia

South Korea Approves World's First Recombinant Anthrax Vaccine BARYTHRAX

CS Diagnostics Submits Patent Application for CS-Protect Hydrogel Organ Spacer Device

Recombinant Zoster Vaccine Shows Strong Efficacy and Safety Profile in Rheumatoid Arthritis Patients

LZ901 Recombinant Herpes Zoster Vaccine Demonstrates 91.6% Efficacy in Phase III Trial Published in Nature Communications

GC Biopharma's BARYTHRAX Becomes World's First Recombinant Anthrax Vaccine to Show Protective Immunity in Phase 2 Trial

Global Vaccine Sales Market to Reach US$141.40 Billion by 2036 as Next-Generation Platforms Accelerate Growth

FDA Grants Fast Track Designation to CS-1103 for Fentanyl Overdose Reversal

FDA Grants Fast Track Designation to CS-1103 for Methamphetamine Overdose Treatment

CorrectSequence's Base-Editing Therapy CS-206 Shows 15-Month VOC-Free Success in Sickle Cell Disease Patient

Page 1 of 364